Track market-moving stories before they get noisy

On June 04, 2026, Park Hotels & Resorts Inc PK shares rose 3.9% to $14.04, reflecting a strong performance amidst a volatile market. The stock has traded within a 52-week range of $9.84 to $14.11, showcasing significant growth over the past year.

GF Value™ verdict: Current price of $14.04 is 2.6% overvalued compared to the GF Value™ of $13.69.GF Score™ of 78/100 indicates that PK is above average in terms of its investment quality.Notable signal: No insider transactions have been recorded in the last 3 months. Is PK Overvalued or Undervalued? The current price of Park Hotels & Resorts Inc PK at $14.04 is slightly above the GF Value™ estimate of $13.69, indicating that the stock is approximately 2.6% overvalued. This valuation suggests that there may be limited margin for safety for new investors looking to enter the stock at this level. The GF Valuation label classifies the stock as fairly valued, which implies that while the company may have solid fundamentals, the current market price does not present a significant opportunity for upside risk.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Being overvalued entails risks, particularly if market sentiment shifts or if the company’s operational performance does not meet investor expectations in the near future.

How Does PK's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 38.4x 17.4x Park Hotels & Resorts Inc PK is currently trading at a forward P/E of 38.4x, which is significantly higher than its 5-year median P/E of 17.4x. This indicates that the stock is trading above its historical valuation metrics, which aligns with the GF Value™ verdict of being overvalued. The high forward P/E suggests that investors are paying a premium for expected future growth, but it also raises concerns about the sustainability of the price increase if the growth outlook does not materialize.

What Does PK's GF Score™ Tell Us? Metric Rating GF Score™ 78/100 Financial Strength 4/10 Profitability 7/10 Growth 5/10 Valuation 9/10 Momentum 8/10 The GF Score™ of 78/100 indicates that Park Hotels & Resorts Inc PK has above-average investment quality. The strongest area is its Valuation rank of 9/10, suggesting that the stock has favorable valuation metrics relative to its peers. However, the Financial Strength score of 4/10 signals potential concerns regarding the company's financial stability. Profitability and Momentum ranks are moderately strong at 7/10 and 8/10, respectively, indicating that the company is performing well in terms of profits and stock performance momentum.

What Are Insiders Doing with PK Stock? There have been no insider transactions in the last 3 months for Park Hotels & Resorts Inc PK . This lack of activity may suggest that insiders are not currently taking positions that could indicate a strong belief in the stock's future performance, either positively or negatively. Absence of insider buying could imply that insiders are not confident in the stock's current valuation or future prospects.

What This Means for Investors Based on the GF Value™ assessment, Park Hotels & Resorts Inc PK is currently overvalued at $14.04 compared to the estimated fair value of $13.69. Investors may want to consider the risks associated with entering a position at this price level, especially given the high forward P/E ratio and the absence of insider activity in recent months.

For the complete analysis, visit the Park Hotels & Resorts Inc PK stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is PK's GF Score™?

The GF Score™ for Park Hotels & Resorts Inc PK is 78/100, indicating that it has an above-average investment quality based on various fundamental metrics.

Is PK overvalued or undervalued?

PK is currently overvalued, with a GF Value™ estimate of $13.69 compared to its current price of $14.04.

What is PK's P/E ratio?

The current forward P/E for Park Hotels & Resorts Inc PK is 38.4x, which is significantly higher than its historical 5-year median P/E of 17.4x, indicating that the stock is trading above its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned development in patients with generalized anxiety disorder (GAD).

The MAD data showed that seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses that reduce liver exposure and are projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine’s clinical use. GlyphAgo AUC0-24 and Cmax increased dose-dependently over the range of doses studied, and agomelatine exposures following GlyphAgo administration in the MAD portion were consistent with data from the SAD and crossover portions of the trial. There was no unmodified agomelatine arm in the MAD portion.

Across all dose levels evaluated, GlyphAgo was well tolerated, with no serious or severe adverse events, no liver-related adverse events, and no clinically significant changes in liver-related laboratory parameters observed, further supporting observations from the SAD and crossover cohorts.

“We are enthusiastic about the data from our Phase 1 program for GlyphAgo, where we’ve now observed consistent safety, tolerability, and PK across all cohorts,” said Daphne Zohar, Co-Founder and Chief Executive Officer of Seaport Therapeutics. “We believe these results substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo. The complete Phase 1 data package further validates our Glyph platform and supports the advancement of GlyphAgo into two parallel Phase 2 trials as we work to bring a new treatment option to patients with generalized anxiety disorder who have not had a new medicine approved in almost 20 years.”

The Phase 1 proof-of-concept trial, which included 174 participants, was conducted in multiple parts to evaluate the safety, tolerability, and PK of GlyphAgo and to compare the PK of GlyphAgo to agomelatine alone. The trial included SAD and MAD cohorts, as well as a crossover portion (including both food-effect and within-participant comparison between GlyphAgo and agomelatine), using both open-label and placebo-controlled designs.

In the previously reported results from the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared with orally administered unmodified agomelatine. GlyphAgo also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to bypass first-pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives.

Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026.This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028. Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028. Seaport plans to present additional analyses from the Phase 1 trial at future upcoming scientific meetings.

About GlyphAgoTM (SPT-320 or Glyph Agomelatine)

GlyphAgo is a novel, “Glyphed” oral prodrug of agomelatine, a clinically validated anti-anxiety and antidepressant that is approved for the treatment of GAD in Australia and Major Depressive Disorder in Australia and the European Union. Using Seaport’s proprietary GlyphTM platform, GlyphAgo is designed to enhance lymphatic absorption and avoid first-pass liver metabolism, thereby enhancing oral bioavailability and reducing side effects. By leveraging an alternative absorption pathway via the intestinal lymphatic system used by dietary fats, GlyphAgo is designed to increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on the data generated to date, Seaport believes GlyphAgo has the potential to become a leading treatment for GAD.

About Seaport Therapeutics

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding our product candidates, preclinical and clinical development activities and timelines, including projected data announcements, and our expectations for future operations and financial performance. These statements include, among other things, Seaport Therapeutics’ expectations regarding the concurrent Phase 2 trials of GlyphAgo (SPT-320), including the expected trial design and the timing of topline data.

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Seaport Therapeutics’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; Seaport Therapeutics’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Seaport Therapeutics’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Seaport Therapeutics’ intellectual property protections; and risks related to the competitive landscape for Seaport Therapeutics’ product candidates; as well as other risks described in “Risk Factors,” in Seaport Therapeutics’ Registration Statement on Form S-1 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. Seaport Therapeutics expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Seaport uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260608037260/en/

Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO PR Newswire

SAN JOSE, Calif., June 11, 2026

– Dr. Davey Smith, a Leading U.S. Infectious Disease Expert: "XAFTY® Should Be Urgently Tested to See if it Can Address the Ebola Crisis"

– Lab testing confirms potency against Ebola (IC50) stronger than against COVID-19, trials or emergency use should move quickly given previous human safety data

– Presents an emergency-administration track and regulatory rationale based on the WHO emergency-use guideline of Monitored Emergency Use of Unregistered and Experimental Interventions (MEURI)

, /PRNewswire/ -- Hyundai Bioscience USA announced on June 10 that it has pledged to provide its broad-spectrum antiviral candidate, XAFTY® (CP-COV03), free of charge for emergency use and/or testing for patients in African countries experiencing Ebola outbreaks.

The decision came after Dr. Davey Smith, a virologist and clinical trial expert at University of California San Diego, proposed to Hyundai Bioscience USA the rapid testing of a potential therapeutic and/or prophylactic for Ebola patients in Africa. Agreeing with Dr. Smith's proposal, Hyundai Bioscience USA decided to submit an official letter conveying the proposal to the WHO and to the health authorities of the affected countries.

No-cost clinical supply and rapid testing under emergency provisions based on expert medical judgmentDr. Smith proposed the testing of XAFTY® for Ebola based on his expert judgment that the spread of high-fatality Ebola constitutes a grave emergency, and that XAFTY® meets the conditions for immediate testing under current MEURI rules.

According to the WHO MEURI framework , in a fatal-epidemic emergency for which there is no treatment alternative, a candidate may be administered to patients pre-emptively—even before formal approval, and even if an immediate clinical trial cannot be launched—provided that minimal scientific data (such as cell-based/in vitro results) and clinical safety have been secured.1 2 This is an international public-health mechanism allows the emergency use of unapproved drugs under defined conditions, placing the highest priority on trying to save lives in a crisis.

Dr. Smith considered XAFTY® to fully satisfy these provisions (i.e., in vitro activity and strong human safety profile). Accepting the proposal, Hyundai Bioscience USA plans to respond to the crisis by supplying its stored XAFTY® free of charge and immediately upon request from WHO or local authorities.

Company-Funded Trial Support to Enable Rapid Clinical Evaluation At the same time, the proposal includes a contingency in case the WHO or local health authorities judge that, even amid the crisis, a rapid clinical trial to verify efficacy is more appropriate than immediate emergency administration (MEURI).

Typically, when a country or institution conducts a trial on its own during a public-health crisis, it takes a long time owing to complex procedures and budget-securing issues. Dr. Smith asked Hyundai Bioscience USA whether it would be willing to bear the trial costs directly to shorten this timeline, and the company agreed to deploy a local trial rapidly at its own expense if necessary.

In particular, XAFTY® possesses a firm human drug history that allows it to enter trials immediately in a crisis. Under the guidelines of the International Council for Harmonisation (ICH), a drug whose safety has already been established through large-scale human administration (Phase 2 or higher) may, in a public-health emergency, skip time-consuming animal-efficacy testing and enter clinical trials immediately.3 XAFTY® has already secured human data by successfully completing a 300-person COVID-19 trial in Korea.4 Further, in vitro results showed that the IC50 (the drug concentration that inhibits viral replication by 50%) of XAFTY®'s active ingredient against the Ebola virus produced strong inhibition even at a lower concentration than against SARS-CoV-2, the virus that causes COVID-19.

Jason Kim, President of Hyundai Bioscience USA, said, "In high-fatality diseases such as Ebola, treatment opportunities must not be missed because of procedures and costs." He added, "We decided to provide the drug free of charge and to conduct a company-funded trial to save as many lives as possible. This decision was made because the spread of this highly-fatal virus cannot wait for conventional procedures."

Hyundai Bioscience USA, a member of the U.S. Department of Defense's Medical CBRN Defense Consortium (MCDC), added that the XAFTY® clinical drug it has offered to provide to the affected countries is stored in compliance with regulations and is kept ready for rapid supply once the necessary procedures are completed.

Mr. Kim added, "The very reason a broad-spectrum antiviral exists is to have a therapy readily available when a new virus emerges and threatens lives," and "We hope the WHO and each country's health authorities will reach a rapid and transparent decision by scientifically weighing the therapeutic benefit against the potential risk."

[References]

World Health Organization. Emergency use of unproven clinical interventions outside clinical trials: ethical considerations. Technical document. Geneva: WHO; 25 March 2025. ISBN 9789240041745.World Health Organization. Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD). 17 May 2018.International Council for Harmonisation. M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Current Step 4 version, 11 June 2009. Section 1.3.Kim JH, Kym S, Kim S-W, et al. A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19. Nat Commun. 2025;16:7084. doi:10.1038/s41467-025-62423-4[Appendix] Supporting Materials

[Appendix 1] The Origins of XAFTY® and the Development of a Broad-Spectrum Antiviral

Witnessing civil-society solidarity and launching development: XAFTY®'s development began in the early days of the 2020 COVID-19 pandemic, as the company witnessed the "Clap for Carers" civic movement that spread from London to major cities around the world. Seeing the solidarity between the healthcare workers who cared for patients despite the risk of infection and the citizens who supported them, Hyundai Bioscience took up therapeutic development out of a sense of responsibility that, as a drug-development company, it too should make a tangible technological contribution.Shortening pandemic cycles and defenseless exposure without alternatives: At the time, Hyundai Bioscience analyzed data from the earlier SARS (2003) and MERS (2012) outbreaks and noted the scientific reality that the cycle of new viral epidemics was steadily shortening. Although a pandemic of variant viruses was a foreseeable future, the global pharmaceutical industry had not established in advance a universal treatment platform capable of responding immediately. As a result, in the early days of COVID-19, elderly and frail people isolated in nursing homes and underserved medical areas faced the tragic reality of mass death—left defenseless, with no therapeutic available.A disgrace the pharmaceutical industry must never repeat: Analyzing the large-scale loss of life that occurred in nursing homes, the company engaged in deep self-reflection. It concluded that allowing humanity to be left so defenseless—and to suffer such collective loss—even in the face of an entirely foreseeable shortening of viral cycles was a disgrace and a gap on the part of the pharmaceutical industry as a whole. The conviction that such defenseless sacrifice must never recur became the foundation of XAFTY®'s development.A latecomer's reversal—turning crisis into opportunity: At a time when global pharmaceutical giants such as Pfizer and Merck had moved first to develop therapeutics targeting the specific COVID-19 virus, Hyundai Bioscience was clearly a latecomer. Yet the company turned the disadvantage of late entry into an opportunity. Rather than settling for a drug that treats only the COVID-19 in front of it, it resolved to create a "universal antiviral" capable of addressing even the unknown variant pandemics of the future with a single drug. It treated the pandemic situation—where trial patients were concentrated—as an opportunity to rapidly verify the efficacy of a broad-spectrum drug.The historic precedent of penicillin and a host-cell-targeting mechanism: Just as human average life expectancy was extended by more than 20 years—even without vaccines—after the appearance of penicillin, the first broad-spectrum antibiotic of the 20th century, the company judged that, in the viral-disease domain as well, a universal therapeutic capable of subduing multiple viruses with a single drug is essential. To solve "drug resistance," the chronic limitation of existing targeted therapeutics, it adopted an innovative paradigm that targets the "host-directed pathway" the virus uses to replicate, rather than the virus itself. The philosophy of administering treatment rapidly at the early symptomatic stage—without diagnostic delay for confirmation—to save lives when a new variant emerges: this is the very essence and development story of XAFTY®.[Appendix 2] Dr. Davey Smith's Global Authority in Infectious Diseases and Key Clinical Credentials

Infectious-disease command at a top-tier global research institution: Dr. Davey Smith currently serves as Chief of the Division of Infectious Diseases and Global Public Health at UC San Diego (UCSD). He is a medical authority who has gone beyond basic infectious-disease research to connect real-world clinical practice with public-health policy and to help establish global standards for treating infectious diseases.Lead of the world's largest U.S. government (NIH)-led pandemic trial: During the COVID-19 pandemic, he served as Lead Principal Investigator of the global ACTIV-2 program, into which the U.S. government (NIH) poured an enormous national budget to accelerate therapeutic development worldwide. He rigorously evaluated the candidate therapeutics of numerous global pharmaceutical companies and personally designed and directed multinational trial protocols, gaining experience overseeing global health infrastructure at the front line of pandemic-crisis response.Field experience and clinical control of high-fatality viruses in Africa: He participated as a key investigator in large-scale global clinical trials (such as STOMP) that the U.S. NIH's National Institute of Allergy and Infectious Diseases (NIAID) pursued to address African endemic disease and the global Mpox crisis. Through this, he has gained the most accurate and deep insight into Africa's under-resourced public-health infrastructure, the clinical control of high-risk viruses, and practical cooperation with local health authorities.[Appendix 3] Dr. Davey Smith's Assessment of the Ebola Crisis and the Background to the XAFTY® Proposal

The urgency of Ebola's spread and the necessity of deploying a universal therapeutic: Dr. Smith assessed that the current spread of Ebola in Africa is a grave public-health crisis. In particular, comparing it with Vietnam's dengue outbreak—where flexible regulatory innovation was demonstrated by approving a rapid XAFTY® trial to help overcome the crisis—he judged that, because Ebola's fatality is equal to or greater, the rapid deployment of a "universal antiviral" that can work immediately regardless of variant is essential.Scientific validity based on data for 33 viruses across 16 families: The core basis for Dr. Smith's designation of XAFTY® as an Ebola treatment alternative lies in the broad-spectrum profile of its main active ingredient, niclosamide. According to numerous publications, niclosamide has demonstrated strong in vitro inhibitory activity against 33 major human-infecting viruses representing 16 viral families. This is thanks to a mechanism that modulates the host cell's autophagy pathway, and Ebola, too, can be effectively addressed through this approach.Pre-established human safety and risk–benefit analysis: XAFTY® has already secured human safety data (Human Data)—including the attainment of blood drug concentrations in the body—by completing a 300-subject COVID-19 Phase 2/3 trial in Korea. Vietnam's Ministry of Health likewise approved a dengue trial without animal-efficacy testing on the basis of this scientific data. Dr. Smith analyzed that, rather than the risk of waiting months for animal testing amid a shortage of BSL-4 facilities, the therapeutic benefit obtained by administering a drug already confirmed safe is overwhelmingly greater.[Appendix 4] International Guidelines for Emergency Clinical Trials and Administration, and the Validity of XAFTY®'s Drug History

1. The WHO emergency-use rule (MEURI framework) and emergency validity: The WHO's MEURI guideline is an official provision that permits even an unapproved drug—provided that safety data exist and the scientific basis is clear—to be administered pre-emptively to patients during the spread of an infectious disease for which there is no treatment alternative. Because XAFTY® has secured a firm safety profile, Dr. Smith judged that the current Ebola emergency fully meets these conditions.2. Grounds for company-funded trial entry and omission of animal testing in a crisis (ICH rules): Under the guidelines of the International Council for Harmonisation (ICH), a drug whose safety has already been established through large-scale human administration (Phase 2 or higher) may, in a public-health emergency, skip animal-efficacy testing and immediately enter clinical trials.3. Immediate-trial feasibility based on XAFTY®'s drug history: XAFTY® has already secured COVID-19 human data (Human Data). The U.S. affiliate's offer to bear the full cost and support a rapid trial is a realistic and scientific alternative that uses the fast track permitted under international rules to lawfully save patients.[Appendix 5] Broad-Spectrum Profile and in vitro (Cell-Based) Results of the Active Ingredient Niclosamide

Antiviral activity against 33 viruses across 16 families: Niclosamide, XAFTY®'s main ingredient, showed meaningful antiviral activity at the cellular level against 33 human-infecting viruses belonging to 16 viral families. Because it assists the cell's autophagy mechanism rather than directly attacking a specific virus, it is resilient to variants.Ebola virus IC50 analysis: When the IC50—the concentration required to inhibit by 50% the activity of a virus, cell, enzyme, or the like—was measured, XAFTY®'s IC50 against the Ebola virus was superior (i.e., at a lower concentration) to that against COVID-19, whose efficacy has been proven in human trials, or against dengue virus, currently in trials.Pharmacokinetic (PK) validity: On the basis of the blood drug concentrations in the body confirmed through the trial in 300 COVID-19 patients, the Ebola virus, too, can be expected to show sufficiently effective inhibitory activity within the existing dosing range. View original content to download multimedia:https://www.prnewswire.com/news-releases/hyundai-bioscience-usa-offers-free-drug-supply-and-funding-for-clinical-trials-to-who-302797761.html

SOURCE Hyundai Bioscience

Dimensional Fund Advisors LP raised its holdings in Zurn Elkay Water Solutions Cor (NYSE: ZWS) by 1.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,562,543 shares of the company's stock after buying an additional 32,381 shares during the quarter. Dimensional Fund

Posted by Defense World Staff on Apr 7th, 2026

GD Culture Group (NASDAQ:GDC – Get Free Report) and Zurn Elkay Water Solutions Cor (NYSE:ZWS – Get Free Report) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Volatility and Risk GD Culture Group has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Zurn Elkay Water Solutions Cor has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership 0.6% of GD Culture Group shares are held by institutional investors. Comparatively, 83.3% of Zurn Elkay Water Solutions Cor shares are held by institutional investors. 1.5% of GD Culture Group shares are held by insiders. Comparatively, 2.4% of Zurn Elkay Water Solutions Cor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings This is a breakdown of current recommendations for GD Culture Group and Zurn Elkay Water Solutions Cor, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GD Culture Group 1 0 0 0 1.00 Zurn Elkay Water Solutions Cor 0 5 4 0 2.44 Zurn Elkay Water Solutions Cor has a consensus target price of $51.63, indicating a potential upside of 14.31%. Given Zurn Elkay Water Solutions Cor’s stronger consensus rating and higher probable upside, analysts plainly believe Zurn Elkay Water Solutions Cor is more favorable than GD Culture Group.

Profitability This table compares GD Culture Group and Zurn Elkay Water Solutions Cor’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets GD Culture Group N/A -7.81% -7.76% Zurn Elkay Water Solutions Cor 11.68% 16.54% 9.82% Valuation and Earnings This table compares GD Culture Group and Zurn Elkay Water Solutions Cor”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GD Culture Group N/A N/A -$186.88 million ($5.35) -0.56 Zurn Elkay Water Solutions Cor $1.70 billion 4.46 $198.00 million $1.15 39.27 Zurn Elkay Water Solutions Cor has higher revenue and earnings than GD Culture Group. GD Culture Group is trading at a lower price-to-earnings ratio than Zurn Elkay Water Solutions Cor, indicating that it is currently the more affordable of the two stocks.

Summary Zurn Elkay Water Solutions Cor beats GD Culture Group on 12 of the 13 factors compared between the two stocks.

About GD Culture Group (Get Free Report)

GD Culture Group Limited operates as an integrated marketing service agency. The company focuses on enterprise brand management, crisis public relations, intelligent public opinion monitoring, media PR, financial and economic we-media operation, digital face application, exhibition services, and other businesses. It also publishes books in corporate history, finance, and economics, as well as plans and organizes online and offline activities, such as new book launches and book sharing sessions to promote new books and build influence and reputation for the corporate clients. The company was formerly known as Code Chain New Continent Limited and changed its name to GD Culture Group Limited in January 2023. GD Culture Group Limited is based in Wan Chai, Hong Kong.

About Zurn Elkay Water Solutions Cor (Get Free Report)

Zurn Elkay Water Solutions Corporation engages in design, procurement, manufacture, and marketing of water management solutions in the United States, Canada, and internationally. It offers water safety and control products, such as backflow preventers, fire system valves, pressure reducing valves, thermostatic mixing valves, PEX pipings, fittings, and installation tools under the Zurn and Wilkins brand names. The company also provides flow systems products comprising point drains, hydrants, fixture carrier systems, chemical drainage systems; and interceptors and separators, acid neutralization systems, and remote monitoring systems under the Zurn and Green Turtle brands. In addition, it develops, manufactures, and markets remote tank monitoring devices, alarms, software, and services. Further, the company offers sensor-operated flush valves under the AquaSense, Aquaflush, and AquaVantage brands; heavy-duty commercial faucets under the AquaSpec brand; water conserving fixtures under the EcoVantage and Zurn One brands; stainless steel products under the Just Manufacturing brand name, which include stainless steel sinks and plumbing fixtures, and various types of sinks, as well as drinking water dispensing and filtration products under the Elkay and Halsey Taylor brands. It distributes to institutional, commercial, waterworks, and residential end markets through independent sales representatives, plumbing wholesalers, and industry-specific distributors in the waterworks, foodservice, industrial, janitorial, sanitation, and sitework industries. The company was formerly known as Zurn Water Solutions Corporation and changed its name to Zurn Elkay Water Solutions Corporation in July 2022. Zurn Elkay Water Solutions Corporation was incorporated in 1892 and is headquartered in Milwaukee, Wisconsin.

Receive News & Ratings for GD Culture Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GD Culture Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEHead to Head Contrast: Teledyne Technologies (NYSE:TDY) vs. Axon Enterprise (NASDAQ:AXON)

NEXT HEADLINE »Comparing OFS Credit (NASDAQ:OCCI) & TPG (NASDAQ:TPG)

Azzad Asset Management Inc. ADV bought a new position in shares of Zurn Elkay Water Solutions Cor (NYSE:ZWS – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 25,913 shares of the company’s stock, valued at approximately $1,205,000.

Other large investors have also recently added to or reduced their stakes in the company. Alliancebernstein L.P. lifted its position in Zurn Elkay Water Solutions Cor by 1,714.8% during the 3rd quarter. Alliancebernstein L.P. now owns 3,369,731 shares of the company’s stock worth $158,478,000 after buying an additional 3,184,048 shares in the last quarter. MAI Capital Management lifted its position in Zurn Elkay Water Solutions Cor by 120,771.6% during the 3rd quarter. MAI Capital Management now owns 293,718 shares of the company’s stock worth $13,814,000 after buying an additional 293,475 shares in the last quarter. UBS Group AG lifted its position in Zurn Elkay Water Solutions Cor by 157.0% during the 3rd quarter. UBS Group AG now owns 479,166 shares of the company’s stock worth $22,535,000 after buying an additional 292,747 shares in the last quarter. Oberweis Asset Management Inc. bought a new stake in Zurn Elkay Water Solutions Cor during the 3rd quarter worth about $12,510,000. Finally, Fisher Asset Management LLC increased its position in shares of Zurn Elkay Water Solutions Cor by 27.9% during the 3rd quarter. Fisher Asset Management LLC now owns 1,021,874 shares of the company’s stock worth $48,059,000 after purchasing an additional 223,168 shares during the last quarter. Institutional investors own 83.33% of the company’s stock.

Zurn Elkay Water Solutions Cor Stock Up 0.3% Shares of ZWS stock opened at $45.32 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.07 and a current ratio of 3.13. The firm’s 50-day moving average is $47.96 and its 200-day moving average is $47.27. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 1.88 and a beta of 1.07. Zurn Elkay Water Solutions Cor has a 52-week low of $27.74 and a 52-week high of $53.17.

Zurn Elkay Water Solutions Cor (NYSE:ZWS – Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. Zurn Elkay Water Solutions Cor had a net margin of 11.68% and a return on equity of 16.54%. The company had revenue of $407.20 million for the quarter, compared to analysts’ expectations of $400.75 million. During the same period in the prior year, the firm earned $0.32 EPS. Zurn Elkay Water Solutions Cor’s quarterly revenue was up 9.8% compared to the same quarter last year. Sell-side analysts predict that Zurn Elkay Water Solutions Cor will post 1.36 EPS for the current year.

Zurn Elkay Water Solutions Cor Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Friday, February 20th were given a dividend of $0.11 per share. This represents a $0.44 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Friday, February 20th. Zurn Elkay Water Solutions Cor’s payout ratio is 38.26%.

Wall Street Analysts Forecast Growth A number of equities research analysts have recently issued reports on the company. Robert W. Baird set a $56.00 price objective on Zurn Elkay Water Solutions Cor in a research note on Thursday, February 5th. The Goldman Sachs Group reissued a “neutral” rating and issued a $50.00 price objective on shares of Zurn Elkay Water Solutions Cor in a report on Thursday, February 5th. Oppenheimer increased their price objective on Zurn Elkay Water Solutions Cor from $53.00 to $57.00 and gave the company an “outperform” rating in a report on Friday, February 6th. Royal Bank Of Canada increased their price objective on Zurn Elkay Water Solutions Cor from $49.00 to $55.00 and gave the company a “sector perform” rating in a report on Thursday, February 5th. Finally, Zacks Research downgraded Zurn Elkay Water Solutions Cor from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $51.63.

View Our Latest Report on ZWS

Insider Activity In other Zurn Elkay Water Solutions Cor news, Director Timothy J. Jahnke sold 25,000 shares of Zurn Elkay Water Solutions Cor stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $51.18, for a total transaction of $1,279,500.00. Following the completion of the transaction, the director directly owned 266,864 shares of the company’s stock, valued at $13,658,099.52. The trade was a 8.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Jeffrey J. Lavalle sold 6,097 shares of Zurn Elkay Water Solutions Cor stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $51.80, for a total transaction of $315,824.60. Following the transaction, the vice president directly owned 49,803 shares of the company’s stock, valued at approximately $2,579,795.40. This trade represents a 10.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 599,259 shares of company stock valued at $31,225,361. 2.40% of the stock is owned by company insiders.

About Zurn Elkay Water Solutions Cor (Free Report)

Zurn Elkay Water Solutions Corp, trading on the NYSE under the ticker ZWS, is a global provider of water delivery and plumbing products. The company was established in October 2022 through a spin-off from Rexnord Corp, creating a standalone business focused on designing, manufacturing and marketing water system components for residential, commercial and industrial customers.

Through its Zurn segment, the company offers solutions for water delivery, drainage and waste evacuation. Product lines include valves, hydrants, backflow prevention devices, piping systems, fittings and commercial waste stations.

Read More Five stocks we like better than Zurn Elkay Water Solutions Cor Want to see what other hedge funds are holding ZWS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zurn Elkay Water Solutions Cor (NYSE:ZWS – Free Report).

Receive News & Ratings for Zurn Elkay Water Solutions Cor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zurn Elkay Water Solutions Cor and related companies with MarketBeat.com's FREE daily email newsletter.

MILWAUKEE--(BUSINESS WIRE)--Zurn Elkay Water Solutions Schedules First Quarter 2026 Earnings Release and Investor Conference Call.

On April 15, 2026, Zurn Elkay Water Solutions Corp ZWS shares fell 4.0% to a current price of $47.39. The stock has experienced a 52-week range between $29.27 and $53.17, highlighting significant volatility over the past year.

GF Value™ verdict: Current price is $47.39, which is 27.1% overvalued compared to a GF Value™ estimate of $37.28.GF Score™ of 89/100 indicates a strong overall performance in key metrics.Notable signal: Insiders have sold $35.6 million in stock over the last three months, with no purchases reported. Is ZWS Overvalued or Undervalued? According to the GF Value™, Zurn Elkay Water Solutions Corp ZWS is currently overvalued, trading at a price of $47.39 compared to an estimated fair value of $37.28. This represents a 27.1% margin of overvaluation. The GF Valuation label indicates a modestly overvalued status, suggesting that investors may face risks if they enter the stock at current price levels. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

The stock’s current valuation implies that it may not provide an attractive entry point for new investors. The risk associated with purchasing overvalued stocks is that they could decline in price, especially if market sentiment shifts or if the company's performance does not meet expectations. This assessment necessitates a cautious approach for potential investors.

How Does ZWS's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 41.2x 42.1x Forward P/E 28.6x N/A As shown in the table, ZWS's current trailing P/E ratio of 41.2x is slightly below its 5-year median P/E of 42.1x. This indicates that the stock is trading close to its historical valuation, suggesting a mixed view when compared with the GF Value™ verdict of being overvalued. The forward P/E of 28.6x indicates a potentially more attractive valuation in the future if earnings expectations are met.

What Does ZWS's GF Score™ Tell Us? Metric Rating GF Score™ 89 Financial Strength 7/10 Profitability 8/10 Growth 8/10 Valuation 5/10 Momentum 10/10 The GF Score™ of 89/100 reflects a strong position in terms of profitability and growth, both rated at 8/10, indicating robust operational performance and potential for future expansion. However, the valuation rank of 5/10 suggests that the current price may not reflect the intrinsic value of the company. The momentum rank of 10/10 highlights a strong recent performance, but the financial strength rating of 7/10 indicates that while the company is stable, there may be areas for improvement.

What Are Insiders Doing with ZWS Stock? Insider activity for Zurn Elkay Water Solutions Corp has been notably bearish, with insiders selling a total of $35.6 million worth of shares in the last three months and no recorded purchases. This pattern may suggest a lack of confidence among insiders regarding the stock's future performance, which could be interpreted as a cautionary signal for external investors.

Typically, insider selling can indicate that those closest to the company believe the stock is overvalued or that they are seeking liquidity for personal reasons. With no recent buying activity, potential investors might consider this aspect carefully when evaluating their investment decisions.

What This Means for Investors Based on the assessment of GF Value™, Zurn Elkay Water Solutions Corp ZWS is currently overvalued. This suggests that prospective investors may want to consider waiting for a more favorable price point before entering the stock.

For the complete analysis, visit the Zurn Elkay Water Solutions Corp ZWS stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is ZWS's GF Score™?

ZWS's GF Score™ is 89/100, indicating a strong performance across several key metrics that historically correlate with higher long-term returns.

Is ZWS overvalued or undervalued?

According to the GF Value™, ZWS is overvalued, with a current price of $47.39 compared to a fair value estimate of $37.28.

What is ZWS's P/E ratio?

ZWS has a trailing P/E ratio of 41.2x, which is slightly below its 5-year median P/E of 42.1x, suggesting it is trading close to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Zurn Water (ZWS - Free Report) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +11.87%. A quarter ago, it was expected that this motion control and water management company would post earnings of $0.34 per share when it actually produced earnings of $0.36, delivering a surprise of +5.88%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Zurn Water, which belongs to the Zacks Waste Removal Services industry, posted revenues of $433 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.99%. This compares to year-ago revenues of $388.8 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Zurn Water shares have added about 2.8% since the beginning of the year versus the S&P 500's gain of 3.9%.

What's Next for Zurn Water?While Zurn Water has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Zurn Water was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.45 on $472.68 million in revenues for the coming quarter and $1.66 on $1.8 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Waste Removal Services is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Montrose Environmental , another stock in the same industry, has yet to report results for the quarter ended March 2026.

This company is expected to post quarterly earnings of $0.14 per share in its upcoming report, which represents a year-over-year change of +100%. The consensus EPS estimate for the quarter has been revised 17.7% lower over the last 30 days to the current level.

Montrose Environmental's revenues are expected to be $183.72 million, up 3.3% from the year-ago quarter.

MILWAUKEE--(BUSINESS WIRE)-- #EmployeeEngagement--Zurn Elkay Water Solutions (NYSE: ZWS) earned recognition as one of the Top Workplaces USA 2026 and Top Workplaces Southeast Wisconsin 2026. The lists are issued by HR research and technology company Energage and partners USA Today and Milwaukee Journal Sentinel and honor organizations that have created exceptional, people-first cultures. “Recognition like this is meaningful because it comes directly from our associates,” said Todd A. Adams, Chairman and CEO. “It ref.

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Zurn Water (ZWS - Free Report) , a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Zurn Water currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market? In order to see if ZWS is a promising momentum pick, let's examine some Momentum Style elements to see if this motion control and water management company holds up.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For ZWS, shares are up 9.88% over the past week while the Zacks Waste Removal Services industry is up 2.3% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 18.26% compares favorably with the industry's 4.58% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Zurn Water have increased 13.79% over the past quarter, and have gained 54.96% in the last year. On the other hand, the S&P 500 has only moved 3.87% and 32.07%, respectively.

Investors should also pay attention to ZWS's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. ZWS is currently averaging 1,287,575 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with ZWS.

Over the past two months, 4 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost ZWS's consensus estimate, increasing from $1.66 to $1.75 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom LineGiven these factors, it shouldn't be surprising that ZWS is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Zurn Water on your short list.

UVALDE, Texas--(BUSINESS WIRE)-- #sustainablyinspired--Zurn Elkay Water Solutions Corporation (NYSE: ZWS) and Uvalde Consolidated Independent School District (UCISD) today announced the donation of 36 Elkay Pro FiltrationTM filtered bottle filling stations, 19 Elkay® ezH2O® filtered bottle filling stations, 73 Elkay filtration conversion kits and five years of Elkay filters for each of the donated units, ensuring consistent delivery of cleaner, healthier, safer drinking water to students, faculty, staff and community.

On May 28, 2026, Zurn Elkay Water Solutions Corp ZWS shares fell 3.7% to $47.01, continuing a downward trend over the past month with a total decline of 9.6%. The stock has traded within a 52-week range of $35.06 to $53.76.

GF Value™ verdict: Current price $47.01 vs GF Value™ of $40.08 (17.3% overvalued).GF Score™ of 88/100 indicates a strong company with solid fundamentals.Most notable signal: Momentum rank of 10/10 reflects strong recent price performance. Is ZWS Overvalued or Undervalued? Currently, Zurn Elkay Water Solutions Corp is trading at $47.01, which represents a 17.3% premium over its GF Value™ of $40.08. This suggests that the stock is overvalued, indicating a potential risk for investors looking for a margin of safety in their investments. The GF Valuation label classifies ZWS as Modestly Overvalued, which reinforces the notion that the stock price may not accurately reflect its intrinsic value at this time.

GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. The current overvaluation may be concerning for potential investors, as it implies that the stock could be subject to a price correction should future earnings not meet high market expectations.

How Does ZWS's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 37.9x 42.1x (5-Year Median) Forward P/E 26.8x N/A Zurn Elkay's current P/E ratio of 37.9x is 10% below its 5-year median of 42.1x, indicating that the stock is trading below its historical valuation levels. This P/E analysis somewhat aligns with the GF Value™ verdict, as it suggests that while the stock is overvalued relative to its intrinsic value, it is trading at a discount compared to its historical earnings multiple.

What Does ZWS's GF Score™ Tell Us? Metric Rating GF Score™ 88 Financial Strength 7/10 Profitability 8/10 Growth 8/10 Valuation 6/10 Momentum 10/10 The GF Score™ of 88/100 indicates that Zurn Elkay Water Solutions Corp possesses strong fundamentals across several key areas. With high ratings in Profitability (8/10) and Growth (8/10), the company demonstrates solid operational efficiency and the potential for expansion. However, the Valuation rank of 6/10 suggests some caution is warranted at current price levels, especially considering the current overvaluation. The top momentum rank of 10/10 highlights robust recent performance, which may attract growth-focused investors.

What Are Insiders Doing with ZWS Stock? In the last three months, there have been no insider transactions reported for Zurn Elkay Water Solutions Corp. The absence of insider buying or selling can indicate a neutral outlook from those closest to the company, suggesting that insiders may not see significant immediate changes in the company's prospects that would warrant buying or selling at this time.

What This Means for Investors Based on the GF Value™ assessment, Zurn Elkay Water Solutions Corp is currently considered overvalued. While the company shows strong fundamentals according to its GF Score™, potential investors should approach with caution, as the premium over intrinsic value suggests a risk of price correction in the future.

For the complete analysis, visit the Zurn Elkay Water Solutions Corp ZWS stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is ZWS's GF Score™?

ZWS has a GF Score™ of 88/100, indicating strong fundamentals that have historically contributed to higher long-term returns.

Is ZWS overvalued or undervalued?

According to GF Value™, ZWS is currently overvalued, trading at a 17.3% premium over its intrinsic value.

What is ZWS's P/E ratio?

ZWS has a P/E (TTM) ratio of 37.9x, which is 10% below its 5-year median of 42.1x, indicating the stock is trading at a discount relative to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

A month has gone by since the last earnings report for USA Compression Partners (USAC - Free Report) . Shares have added about 6.4% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is USA Compression due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.

USA Compression Q4 Earnings Match Estimates, Revenues Rise Y/YUSA Compression Partners reported a fourth-quarter adjusted net profit of 28 cents per common unit, matching the Zacks Consensus Estimate. The metric improved from the year-ago quarter's adjusted net profit of 18 cents per common unit, driven by a year-over-year increase in average monthly revenue per horsepower.

The largest independent provider of natural gas compression services generated revenues of $252.5 million, improving 2.7% from the year-ago quarter’s level and beating the Zacks Consensus Estimate by $1 million. This growth was due to a 3.9% increase in contract operations and a 3.4% rise in related-party revenues.

Adjusted EBITDA decreased 0.6% to $154.5 million, which missed our estimate of $156.2 million.

USA Compression’s distributable cash flow increased to $103.2 million from $96.3 million in the prior-year quarter. The company reported a net income worth $27.8 million compared with $25.4 million in the year-ago quarter.

The oil and gas equipment and services company reported net operating cash flow of $139.5 million in the fourth quarter, up from the prior-year quarter’s $130.2 million.

Adjusted gross operating margin of 66.8% marked a decrease from the year-ago period’s 68.4%.

The company’s revenue-generating capacity declined slightly year over year to 3.58 million horsepower. However, the figure exceeded our estimate of 3.57 million horsepower.

Further, the average monthly revenue per horsepower rose to $21.69 from $20.85 in the fourth quarter of 2024. The figure was lower than our estimate of $21.91.

Meanwhile, USA Compression’s average quarterly horsepower utilization rate was 94.5%, which was in line with the prior-year quarter’s level.

DCF, Cost, Capex & Balance SheetUSA Compression’s distributable cash flow available to limited partners totaled $103.2 million (providing 1.36x distribution coverage), up 7.2% from the year-ago level.Notably, on Oct. 16, 2025, USA Compression declared cash distribution of 52.5 cents per unit ($2.10 on an annualized basis) in the third quarter. The distribution paid on Nov. 7, 2025, to its common unitholders of record as of Oct. 27.

Notably, on Jan. 15, 2026, USA Compression declared cash distribution of 52.5 cents per unit ($2.10 on an annualized basis) in the fourth quarter. The distribution was paid on Feb. 6, 2026, to its common unitholders of record as of Jan. 26.

The company reported $175.9 million in costs and expenses, up 2.7% from $171.4 million in the year-ago quarter. It spent $40 million on growth capex. Maintenance capex amounted to $7.8 million.

As of Dec. 31, 2025, Dallas, TX-based this oil and gas equipment and services company had a net long-term debt of $2.5 billion.

GuidanceUSA Compression expects its full-year 2026 adjusted EBITDA to be between $770 million and $800 million. This Zacks Rank #2 (Buy) company also expects distributable cash flow to range from $480 million to $510 million, expansion capital expenditures to be between $230 million and $250 million, and maintenance capital expenditures to total in the band of $60 million to $70 million.

How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.

The consensus estimate has shifted -26.6% due to these changes.

VGM ScoresCurrently, USA Compression has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, USA Compression has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.93% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: USA Compression Partners (USAC - Free Report) Founded in 1998, USA Compression Partners, LP is one of the largest independent natural gas compression service providers in the United States, measured by fleet horsepower. Structured as a master limited partnership ("MLP") with the Energy Transfer family owning approximately 48%, it primarily focuses on large-horsepower applications (greater than 1,000 horsepower) in some areas, including the Permian/Delaware, Marcellus/Utica, Mid-Continent/SCOOP/STACK, South Texas, East Texas, Louisiana, Rockies. The firm is also involved in engineering, design, operation, service, and repair of compressor units.

USAC is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Oils-Energy stock. USAC has a Momentum Style Score of B, and shares are up 3.1% over the past four weeks.

For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.07 to $1.32 per share. USAC boasts an average earnings surprise of +1.2%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, USAC should be on investors' short list.

Key Takeaways Repsol (REPYY), FTI, VIV and USAC passed a screen based on superior efficiency ratios versus peers.High receivables, inventory turnover, asset use and margins signal stronger profit generation potential.REPYY, FTI, VIV and USAC also posted positive four-quarter earnings surprises, supporting strength. Efficiency level assesses a company’s capability to transform usable input into output, and is commonly considered an essential parameter for gauging its potential to generate profits. A company with a high efficiency level is expected to provide stellar returns, as it is believed to be positively correlated with price performance.

However, at times, it becomes difficult to measure the efficiency level of a company. This is why one must consider the popular efficiency ratios listed below while selecting stocks.

The stocks of Repsol (REPYY - Free Report) , TechnipFMC (FTI - Free Report) , Telefonica Brasil (VIV - Free Report) and USA Compression Partners (USAC - Free Report) made it through the screening process:

These efficiency ratios are:

Receivables Turnover: This is the ratio of 12-month sales to four-quarter average receivables. It shows a company’s potential to extend its credit and collect debt in terms of that credit. A high receivables turnover ratio, or the “accounts receivable turnover ratio” or “debtor’s turnover ratio” is desirable as it shows that the company is capable of collecting its accounts receivables or that it has quality customers.

Asset Utilization: This ratio indicates a company’s capability to convert assets into output and is thus a widely known measure of efficiency level. It is calculated by dividing total sales over the past 12 months by the last four-quarter average of total assets. Like the above ratios, high asset utilization may indicate that a company is efficient.

Inventory Turnover: The ratio of the 12-month cost of goods sold (COGS) to a four-quarter average inventory is considered one of the most popular efficiency ratios. It indicates a company’s ability to maintain a suitable inventory position. While a high value indicates that the company has a relatively low level of inventory compared to COGS, a low value indicates that the company is facing declining sales, which has resulted in excess inventory.

Operating Margin: This efficiency measure is the ratio of operating income over the past 12 months to sales over the same period. It measures a company’s ability to control operating expenses. Hence, a high value of the ratio may indicate that the company manages its operating expenses more efficiently than its peers.

Screening CriteriaIn addition to the above-mentioned ratios, we have added a favorable Zacks Rank — Zacks Rank #1 (Strong Buy) — to the screen to make this strategy more profitable. You can see the complete list of today’s Zacks #1 Rank stocks here.

Inventory Turnover, Receivables Turnover, Asset Utilization, and Operating Margin greater than the industry average(Values of these ratios higher than industry averages may indicate that the efficiency level of the company is higher than its peers.)   

The use of these few criteria narrowed down the universe of over 7,906 stocks to 18.

Here are the top four stocks that made it through the screen:

Repsol

Repsol explores, develops and produces crude oil products and natural gas, transports petroleum products and liquified petroleum gas and refines petroleum. REPYY has an average four-quarter earnings surprise of 18.7%.

TechnipFMC

TechnipFMC is a leading manufacturer and supplier of products, services and fully integrated technology solutions for the energy industry. FTI has an average four-quarter earnings surprise of 15.9%.

Telefonica Brasil

Telefonica Brasil is engaged in providing communication, information and entertainment solutions in the telecommunication sector, in the State of Sao Paulo. VIV has an average four-quarter earnings surprise of 7.7%.

USA Compression Partners

USA Compression Partners is one of the largest independent natural gas compression service providers in the United States, measured by fleet horsepower. USAC has an average four-quarter earnings surprise of 1.2%.

USA Compression Partners is rated a cautious buy, offering a stable 7.8% forward yield and improving distribution coverage post-acquisition. USAC's $860M J-W Power acquisition boosts EBITDA guidance to $770–800M and DCF to $480–510M for 2026, raising coverage to ~1.6x. Leverage remains a constraint at ~3.2–3.3x EBITDA, making deleveraging a priority for retained cash rather than shareholder returns.

DALLAS--(BUSINESS WIRE)--USA Compression Partners, LP (NYSE: USAC) (“USA Compression” or the “Partnership”) announced today its financial and operating results for first-quarter 2026.

Financial Highlights

Total revenues of $331.3 million for first-quarter 2026, compared to $245.2 million for first-quarter 2025. Net income was $38.3 million for first-quarter 2026, compared to $20.5 million for first-quarter 2025. Net cash provided by operating activities was $86.1 million for first-quarter 2026, compared to $54.7 million for first-quarter 2025. Adjusted EBITDA was $188.6 million for first-quarter 2026, compared to $149.5 million for first-quarter 2025. Distributable Cash Flow was $130.8 million for first-quarter 2026, compared to $88.7 million for first-quarter 2025. Distributable Cash Flow Coverage Ratio was 1.72x for first-quarter 2026, compared to 1.44x for first-quarter 2025. Announced cash distribution of $0.525 per common unit for first-quarter 2026, consistent with first-quarter 2025. Strategic Highlights

Acquired J-W Power Company and its parent company, J-W Energy Company (the “J-W Power Acquisition”), adding over 0.8 million active horsepower across key regions, including the Northeast, Mid-Continent, Rockies, Gulf Coast, and Permian Basin, creating a combined fleet of approximately 4.4 million active horsepower. Operational Highlights

Average revenue per revenue-generating horsepower per month of $22.73 for first-quarter 2026, compared to $21.06 for first-quarter 2025. Average revenue-generating horsepower of 4.44 million for first-quarter 2026, compared to 3.56 million for first-quarter 2025. Average horsepower utilization of 91.9% for first-quarter 2026, compared to 94.4% for first-quarter 2025. “First-quarter results reflect steady demand and strong operational execution,” said Clint Green, President and CEO. “Since closing the highly accretive J-W Power Acquisition on January 12, our first quarter results reflect improvement in metrics for leverage, cash flow and distribution coverage. Looking ahead, we are encouraged by the J-W cultural alignment across the organization and have visibility into improved earnings of the combined assets. Additionally, as new engine procurement lead times have recently moved out beyond two years, the acquisition of a high-quality fleet and customer base is certainly well-timed. Looking ahead, we remain focused on executing consistently, generating reliable cash flows that support our distribution, and building on first quarter momentum throughout 2026.”

Expansion capital expenditures were $26.4 million, maintenance capital expenditures were $9.2 million, and cash interest expense, net was $47.1 million for first-quarter 2026.

The results of operations of J-W Power Company, and its parent company, J-W Energy Company, subsequent to their acquisition on January 12, 2026 are reflected in the Partnership’s financial results for first-quarter 2026.

On April 16, 2026, the Partnership announced a first-quarter cash distribution of $0.525 per common unit, which corresponds to an annualized distribution rate of $2.10 per common unit. The distribution will be paid on May 8, 2026, to common unitholders of record as of the close of business on April 27, 2026.

Operational and Financial Data

Three Months Ended

March 31,
2026

December 31,
2025

March 31,
2025

Operational data:

Fleet horsepower (at period end) (1)

4,930,737

3,894,332

3,859,920

Revenue-generating horsepower (at period end) (2)

4,439,968

3,585,452

3,559,624

Average revenue-generating horsepower (3)

4,438,366

3,579,179

3,557,164

Revenue-generating compression units (at period end)

6,430

4,256

4,213

Horsepower utilization (at period end) (4)

92.0

%

94.7

%

94.4

%

Average horsepower utilization (for the period) (4)

91.9

%

94.5

%

94.4

%

Financial data ($ in thousands, except per horsepower data):

Total revenues

$

331,275

$

252,484

$

245,234

Average revenue per revenue-generating horsepower per month (5)

$

22.73

$

21.69

$

21.06

Net income

$

38,342

$

27,760

$

20,512

Operating income

$

91,411

$

76,569

$

69,391

Net cash provided by operating activities

$

86,103

$

139,488

$

54,651

Gross margin

$

126,227

$

96,388

$

93,223

Adjusted gross margin (6)

$

213,373

$

168,748

$

163,616

Adjusted gross margin percentage (7)

64.4

%

66.8

%

66.7

%

Adjusted EBITDA (6)

$

188,587

$

154,499

$

149,514

Adjusted EBITDA percentage (7)

56.9

%

61.2

%

61.0

%

Distributable Cash Flow (6)

$

130,793

$

103,211

$

88,695

Distributable Cash Flow Coverage Ratio (6)

1.72x

1.36x

1.44x

____________________ (1)

Fleet horsepower is horsepower for compression units that have been delivered to the Partnership and excludes 14,985, 14,985, and 13,210 of non-marketable horsepower as of March 31, 2026, December 31, 2025, and March 31, 2025, respectively. As of March 31, 2026, we had 61,350 large horsepower on order for delivery, all of which is expected to be delivered within the next 12 months.

(2)

Revenue-generating horsepower is horsepower under contract for which the Partnership is billing a customer.​

(3)

Calculated as the average of the month-end revenue-generating horsepower for each of the months in the period.​

(4)

Horsepower utilization is calculated as (i) the sum of (a) revenue-generating horsepower; (b) horsepower in the Partnership’s fleet that is under contract but is not yet generating revenue; and (c) horsepower not yet in the Partnership’s fleet that is under contract but not yet generating revenue and that is expected to be delivered, divided by (ii) total available horsepower less idle horsepower that is under repair.

Horsepower utilization based on revenue-generating horsepower and fleet horsepower was 90.0%, 92.1%, and 92.2% at March 31, 2026, December 31, 2025, and March 31, 2025, respectively.

Average horsepower utilization based on revenue-generating horsepower and fleet horsepower was 90.2%, 92.1%, and 91.9% for the three months ended March 31, 2026, December 31, 2025, and March 31, 2025, respectively.

(5)

Calculated as the average of the result of dividing the contractual monthly rate, excluding standby or other temporary rates, for all units at the end of each month in the period by the sum of the revenue-generating horsepower at the end of each month in the period.

(6)

Adjusted gross margin, Adjusted EBITDA, Distributable Cash Flow, and Distributable Cash Flow Coverage Ratio are all non-U.S. generally accepted accounting principles (“Non-GAAP”) financial measures. For the definition of each measure, as well as reconciliations of each measure to its most directly comparable financial measures calculated and presented in accordance with GAAP, see “Non-GAAP Financial Measures” below.

(7)

Adjusted gross margin percentage and Adjusted EBITDA percentage are calculated as a percentage of revenue.

Liquidity and Long-Term Debt

As of March 31, 2026, the Partnership was in compliance with all covenants under its $1.75 billion revolving credit facility. As of March 31, 2026, the Partnership had outstanding borrowings under the revolving credit facility of $1.25 billion and, after accounting for outstanding letters of credit in the amount of $2.0 million, $497.8 million of remaining unused availability, all of which was available to be drawn, inclusive of restrictions related to compliance with applicable financial covenants. As of March 31, 2026, the outstanding aggregate principal amount of the Partnership’s 7.125% senior notes due 2029 and 6.250% senior notes due 2033 was $1.00 billion and $750.0 million, respectively.

Full-Year 2026 Outlook

USA Compression confirms its full-year 2026 guidance as follows (in thousands):

Full-Year 2026 Outlook

Low

High

Adjusted EBITDA (1)

$

770,000

$

800,000

Distributable Cash Flow (1)

$

480,000

$

510,000

Capital Expenditures:

Expansion capital expenditures (2)

$

230,000

$

250,000

Maintenance capital expenditures

$

60,000

$

70,000

Conference Call

The Partnership will host a conference call today beginning at 11:00 a.m. Eastern Time (10:00 a.m. Central Time) to discuss first-quarter 2026 financial and operating results. The call will be broadcast live over the internet. Investors may participate by audio webcast, or if located in the U.S. or Canada, by phone. A replay will be available shortly after the call via the “Events & Presentations” page of USA Compression’s Investor Relations website.

About USA Compression Partners, LP

USA Compression Partners, LP is one of the nation’s largest independent providers of natural gas compression services in terms of total compression fleet horsepower. USA Compression partners with a broad customer base composed of producers, processors, gatherers, and transporters of natural gas and crude oil. USA Compression focuses on providing midstream natural gas compression services to infrastructure applications primarily in high-volume gathering systems, processing facilities, and transportation applications. More information is available at usacompression.com.

Non-GAAP Financial Measures

This news release includes the Non-GAAP financial measures of Adjusted gross margin, Adjusted EBITDA, Distributable Cash Flow, and Distributable Cash Flow Coverage Ratio.

Adjusted gross margin is defined as revenue less cost of operations, exclusive of depreciation and amortization expense. Management believes Adjusted gross margin is useful to investors as a supplemental measure of the Partnership’s operating profitability. Management uses adjusted gross margin to assess operating performance as compared to historical results, budget and forecast amounts, expected return on capital investment, and our competitors. Adjusted gross margin primarily is impacted by the pricing trends for service operations and cost of operations, including labor rates for service technicians, volume, and per-unit costs for lubricant oils, quantity and pricing of routine preventative maintenance on compression units, and property tax rates on compression units. Adjusted gross margin should not be considered an alternative to, or more meaningful than, gross margin or any other measure presented in accordance with GAAP. Moreover, the Partnership’s Adjusted gross margin, as presented, may not be comparable to similarly titled measures of other companies. Because the Partnership capitalizes assets, depreciation and amortization of equipment is a necessary element of its cost structure. To compensate for the limitations of Adjusted gross margin as a measure of the Partnership’s performance, management believes it is important to consider gross margin determined under GAAP, as well as Adjusted gross margin, to evaluate the Partnership’s operating profitability.

Management views Adjusted EBITDA as one of its primary tools for evaluating the Partnership’s results of operations, and the Partnership tracks this item on a monthly basis as an absolute amount and as a percentage of revenue compared to the prior month, year-to-date, prior year, and budget. The Partnership defines EBITDA as net income (loss) before net interest expense, depreciation and amortization expense, and income tax expense (benefit). The Partnership defines Adjusted EBITDA as EBITDA plus impairment of assets, impairment of goodwill, interest income on capital leases, unit-based compensation expense (benefit), severance charges and other employee costs, certain transaction expenses, loss (gain) on disposition of assets, loss on extinguishment of debt, loss (gain) on derivative instrument, amortization of capitalized SaaS implementation costs, and other. Adjusted EBITDA is used as a supplemental financial measure by management and external users of the Partnership’s financial statements, such as investors and commercial banks, to assess:

the financial performance of the Partnership’s assets without regard to the impact of financing methods, capital structure, or the historical cost basis of the Partnership’s assets; the viability of capital expenditure projects and the overall rates of return on alternative investment opportunities; the ability of the Partnership’s assets to generate cash sufficient to make debt payments and pay distributions; and the Partnership’s operating performance as compared to those of other companies in its industry without regard to the impact of financing methods and capital structure. Management believes Adjusted EBITDA provides useful information to investors because, when viewed in conjunction with the Partnership’s GAAP results and the accompanying reconciliations, it may provide a more complete assessment of the Partnership’s performance as compared to considering solely GAAP results. Management also believes that external users of the Partnership’s financial statements benefit from having access to the same financial measures that management uses to evaluate the results of the Partnership’s business.

Adjusted EBITDA should not be considered an alternative to, or more meaningful than, net income (loss), operating income (loss), cash flows from operating activities, or any other measure presented in accordance with GAAP. Moreover, the Partnership’s Adjusted EBITDA, as presented, may not be comparable to similarly titled measures of other companies.

Distributable Cash Flow is defined as net income (loss) plus non-cash interest expense, non-cash income tax expense (benefit), depreciation and amortization expense, unit-based compensation expense (benefit), impairment of assets, impairment of goodwill, certain transaction expenses, severance charges and other employee costs, loss (gain) on disposition of assets, loss on extinguishment of debt, change in fair value of derivative instrument, proceeds from insurance recovery, amortization of capitalized SaaS implementation costs, and other, less distributions on Preferred Units and maintenance capital expenditures.

Distributable Cash Flow should not be considered an alternative to, or more meaningful than, net income (loss), operating income (loss), cash flows from operating activities, or any other measure presented in accordance with GAAP. Moreover, the Partnership’s Distributable Cash Flow, as presented, may not be comparable to similarly titled measures of other companies.​

Management believes Distributable Cash Flow is an important measure of operating performance because it allows management, investors, and others to compare the cash flows that the Partnership generates (after distributions on Preferred Units but prior to any retained cash reserves established by the Partnership’s general partner and the effect of the Distribution Reinvestment Plan) to the cash distributions that the Partnership expects to pay its common unitholders.

Distributable Cash Flow Coverage Ratio is defined as the period’s Distributable Cash Flow divided by distributions declared to common unitholders in respect of such period. Management believes Distributable Cash Flow Coverage Ratio is an important measure of operating performance because it permits management, investors, and others to assess the Partnership’s ability to pay distributions to common unitholders out of the cash flows the Partnership generates. The Partnership’s Distributable Cash Flow Coverage Ratio, as presented, may not be comparable to similarly titled measures of other companies.

This news release also contains a forward-looking estimate of Adjusted EBITDA and Distributable Cash Flow projected to be generated by the Partnership for its 2026 fiscal year. The Partnership is unable to reconcile projected Adjusted EBITDA and Distributable Cash Flow to projected net income (loss) and projected net cash provided by operating activities, the most comparable financial measures calculated in accordance with GAAP, because components of the required calculations cannot be reasonably estimated, such as changes to current assets and liabilities, unknown future events, and estimating certain future GAAP measures. The inability to project certain components of the calculation would significantly affect the accuracy of the reconciliations.

See “Reconciliation of Non-GAAP Financial Measures” for Adjusted gross margin reconciled to gross margin, Adjusted EBITDA reconciled to net income and net cash provided by operating activities, and net income and net cash provided by operating activities reconciled to Distributable Cash Flow and Distributable Cash Flow Coverage Ratio.

Forward-Looking Statements

Some of the information in this news release may contain forward-looking statements. These statements can be identified by the use of forward-looking terminology including “may,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “continue,” “if,” “project,” “outlook,” “will,” “could,” “should,” or other similar words or the negatives thereof, and include the Partnership’s expectation of future performance contained herein, including as described under “Full-Year 2026 Outlook.” These statements discuss future expectations, contain projections of results of operations or of financial condition, or state other “forward-looking” information. You are cautioned not to place undue reliance on any forward-looking statements, which can be affected by assumptions used or by known risks or uncertainties. Consequently, no forward-looking statements can be guaranteed. When considering these forward-looking statements, you should keep in mind the risk factors noted below and other cautionary statements in this news release. The risk factors and other factors noted throughout this news release could cause actual results to differ materially from those contained in any forward-looking statement. Known material factors that could cause the Partnership’s actual results to differ materially from the results contemplated by such forward-looking statements include:

changes in economic conditions of the crude oil and natural gas industries, including any impact from the ongoing military conflict involving Russia and Ukraine or the conflict in the Middle East; changes in general economic conditions, including inflation, supply chain disruptions, trade tensions or tariff impacts; changes in the long-term supply of and demand for crude oil and natural gas; our ability to realize the anticipated benefits of the J-W Power Acquisition and to integrate the acquired assets with our existing fleet and operations; competitive conditions in the Partnership’s industry, including competition for employees in a tight labor market; changes in the availability and cost of capital, including changes to interest rates; renegotiation of material terms of customer contracts; actions taken by the Partnership’s customers, competitors, and third-party operators; operating hazards, natural disasters, epidemics, pandemics, weather-related impacts, casualty losses, and other matters beyond the Partnership’s control; the deterioration of the financial condition of the Partnership’s customers, which may result in the initiation of bankruptcy proceedings with respect to certain customers; the restrictions on the Partnership’s business that are imposed under the Partnership’s long-term debt agreements; information technology risks, including the risk from cyberattacks, cybersecurity breaches, and other disruptions to the Partnership’s information systems; our ability to realize the anticipated benefits of the shared services integration with Energy Transfer; the effects of existing and future laws and governmental regulations; the effects of future litigation; factors described in Part I, Item 1A (“Risk Factors”) of the Partnership’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2026, as well as our subsequent filings with the SEC; and other factors discussed in the Partnership’s filings with the SEC. All forward-looking statements speak only as of the date of this news release and are expressly qualified in their entirety by the foregoing cautionary statements. Unless legally required, the Partnership undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. Unpredictable or unknown factors not discussed herein also could have material adverse effects on forward-looking statements.

USA COMPRESSION PARTNERS, LP

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except for per unit amounts – Unaudited)

Three Months Ended

March 31,
2026

December 31,
2025

March 31,
2025

Revenues:

Contract operations

$

293,509

$

231,713

$

224,975

Parts and service

21,871

4,165

5,094

Related party

15,895

16,606

15,165

Total revenues

331,275

252,484

245,234

Costs and expenses:

Cost of operations, exclusive of depreciation and amortization

117,902

83,736

81,618

Depreciation and amortization

87,146

72,360

70,393

Selling, general, and administrative

35,357

17,891

18,862

Loss (gain) on disposition of assets

(545

)

1,626

1,325

Impairment of assets

4

302

3,645

Total costs and expenses

239,864

175,915

175,843

Operating income

91,411

76,569

69,391

Other income (expense):

Interest expense, net

(48,966

)

(45,299

)

(47,369

)

Loss on extinguishment of debt

(1

)

(3,006

)

—

Other

20

32

25

Total other expense

(48,947

)

(48,273

)

(47,344

)

Net income before income tax expense

42,464

28,296

22,047

Income tax expense

4,122

536

1,535

Net income

38,342

27,760

20,512

Less: distributions on Preferred Units

—

—

(4,388

)

Net income attributable to common unitholders’ interests

$

38,342

$

27,760

$

16,124

Weighted average common units outstanding – basic

142,750

123,741

117,513

Weighted average common units outstanding – diluted

143,131

124,166

118,254

Basic and diluted net income per common unit

$

0.27

$

0.22

$

0.14

Distributions declared per common unit for respective periods

$

0.525

$

0.525

$

0.525

  USA COMPRESSION PARTNERS, LP

SELECTED BALANCE SHEET DATA

(In thousands, except unit amounts – Unaudited)

March 31,
2026

Selected Balance Sheet Data:

Total assets

$

3,734,442

Long-term debt, net

$

2,980,327

Total partners’ capital

$

316,666

Common units outstanding

144,972,358

  USA COMPRESSION PARTNERS, LP

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands — Unaudited)

Three Months Ended

March 31,
2026

December 31,
2025

March 31,
2025

Net cash provided by operating activities

$

86,103

$

139,488

$

54,651

Net cash used in investing activities

(467,892

)

(51,181

)

(18,041

)

Net cash provided by (used in) financing activities

387,747

(79,743

)

(36,622

)

  USA COMPRESSION PARTNERS, LP

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

ADJUSTED GROSS MARGIN TO GROSS MARGIN

(In thousands — Unaudited)

  The following table reconciles Adjusted gross margin to gross margin, its most directly comparable GAAP financial measure, for each of the periods presented:

  Three Months Ended

March 31,
2026

December 31,
2025

March 31,
2025

Total revenues

$

331,275

$

252,484

$

245,234

Cost of operations, exclusive of depreciation and amortization

(117,902

)

(83,736

)

(81,618

)

Depreciation and amortization

(87,146

)

(72,360

)

(70,393

)

Gross margin

$

126,227

$

96,388

$

93,223

Depreciation and amortization

87,146

72,360

70,393

Adjusted gross margin

$

213,373

$

168,748

$

163,616

  USA COMPRESSION PARTNERS, LP

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA TO NET INCOME AND NET CASH PROVIDED BY OPERATING ACTIVITIES

(In thousands — Unaudited)

  The following table reconciles Adjusted EBITDA to net income and net cash provided by operating activities, its most directly comparable GAAP financial measures, for each of the periods presented:

  Three Months Ended

March 31,
2026

December 31,
2025

March 31,
2025

Net income

$

38,342

$

27,760

$

20,512

Interest expense, net

48,966

45,299

47,369

Depreciation and amortization

87,146

72,360

70,393

Income tax expense

4,122

536

1,535

EBITDA

$

178,576

$

145,955

$

139,809

Unit-based compensation expense (1)

2,405

1,527

3,384

Transaction expenses (2)

3,777

1,914

—

Severance charges and other employee costs (3)

4,085

169

1,351

Loss (gain) on disposition of assets

(545

)

1,626

1,325

Loss on extinguishment of debt (4)

1

3,006

—

Amortization of capitalized SaaS implementation costs

284

—

—

Impairment of assets (5)

4

302

3,645

Adjusted EBITDA

$

188,587

$

154,499

$

149,514

Interest expense, net

(48,966

)

(45,299

)

(47,369

)

Non-cash interest expense

1,829

1,949

2,241

Income tax expense

(4,122

)

(536

)

(1,535

)

Non-cash income tax expense

2,711

—

—

Transaction expenses

(3,777

)

(1,914

)

—

Severance charges and other employee costs

(4,085

)

(169

)

(1,351

)

Other

398

436

85

Changes in operating assets and liabilities

(46,472

)

30,522

(46,934

)

Net cash provided by operating activities

$

86,103

$

139,488

$

54,651

____________________ (1)

For the three months ended March 31, 2026, December 31, 2025, and March 31, 2025, unit-based compensation expense included $0.1 million, $0.4 million, and $0.7 million, respectively, of cash payments related to quarterly payments of distribution equivalent rights on outstanding unit awards and $0.0 million, $2.0 million, and $2.2 million, respectively, related to the cash portion of the settlement of phantom unit awards upon vesting, a portion of which is included in the unit-based compensation expense for these periods.

(2)

Represents certain expenses related to potential and completed transactions, including the J-W Power Acquisition, and other items. The Partnership believes it is useful to investors to exclude these expenses.

(3)

Severance charges and other employee costs includes (i) severance payments to former employees of the Partnership, (ii) retention payments to employees of the Partnership that have executed agreements to maintain operations during the shared services or the J-W Power Acquisition integration but do not intend to remain employed with the Partnership after their retention period, and (iii) relocation payments to employees of the Partnership for relocation resulting from the shared services integration and the relocation of the Partnership’s headquarters to Dallas, Texas. These retention payments are incremental to the affected employees’ base pay. For the three months ended March 31, 2026, severance charges and other employee costs included $0.6 million and $0.2 million related to retention and relocation payments, respectively. For the three months ended December 31, 2025, severance charges and other employee costs included $0.1 million and $(0.1) million related to retention and relocation payments, respectively. For the three months ended March 31, 2025, severance charges and other employee costs included $0.4 million and $0.1 million related to retention and relocation payments, respectively.

(4)

For the three months ended December 31, 2025, the loss on extinguishment of debt of $3.0 million is a result of the redemption of our senior notes due 2027.

(5)

Represents non-cash charges incurred to decrease the carrying value of long-lived assets with recorded values that are not expected to be recovered through future cash flows.

  USA COMPRESSION PARTNERS, LP

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

DISTRIBUTABLE CASH FLOW TO NET INCOME AND NET CASH PROVIDED BY OPERATING ACTIVITIES

(Dollars in thousands — Unaudited)

  The following table reconciles Distributable Cash Flow to net income and net cash provided by operating activities, its most directly comparable GAAP financial measures, for each of the periods presented:

  Three Months Ended

March 31,
2026

December 31,
2025

March 31,
2025

Net income

$

38,342

$

27,760

$

20,512

Non-cash interest expense

1,829

1,949

2,241

Depreciation and amortization

87,146

72,360

70,393

Non-cash income tax expense

2,711

436

85

Unit-based compensation expense (1)

2,405

1,527

3,384

Transaction expenses (2)

3,777

1,914

—

Severance charges and other employee costs (3)

4,085

169

1,351

Other (4)

—

—

1,000

Loss (gain) on disposition of assets

(545

)

1,626

1,325

Loss on extinguishment of debt (5)

1

3,006

—

Impairment of assets (6)

4

302

3,645

Distributions on Preferred Units

—

—

(4,388

)

Amortization of capitalized SaaS implementation costs

284

—

—

Maintenance capital expenditures (7)

(9,246

)

(7,838

)

(10,853

)

Distributable Cash Flow

$

130,793

$

103,211

$

88,695

Maintenance capital expenditures

9,246

7,838

10,853

Transaction expenses

(3,777

)

(1,914

)

—

Severance charges and other employee costs

(4,085

)

(169

)

(1,351

)

Distributions on Preferred Units

—

—

4,388

Other

398

—

(1,000

)

Changes in operating assets and liabilities

(46,472

)

30,522

(46,934

)

Net cash provided by operating activities

$

86,103

$

139,488

$

54,651

Distributable Cash Flow

$

130,793

$

103,211

$

88,695

Distributions for Distributable Cash Flow Coverage Ratio (8)

$

76,110

$

76,109

$

61,731

Distributable Cash Flow Coverage Ratio

1.72x

1.36x

1.44x

____________________ (1)

For the three months ended March 31, 2026, December 31, 2025, and March 31, 2025, unit-based compensation expense included $0.1 million, $0.4 million, and $0.7 million, respectively, of cash payments related to quarterly payments of distribution equivalent rights on outstanding unit awards and $0 million, $2.0 million, and $2.2 million, respectively, related to the cash portion of the settlement of phantom unit awards upon vesting, a portion of which is included in the unit-based compensation expense for these periods.

(2)

Represents certain expenses related to potential and completed transactions, including the J-W Power Acquisition, and other items. The Partnership believes it is useful to investors to exclude these expenses.

(3)

Severance charges and other employee costs includes (i) severance payments to former employees of the Partnership, (ii) retention payments to employees of the Partnership that have executed agreements to maintain operations during the shared services or the J-W Power Acquisition integration but do not intend to remain employed with the Partnership after their retention period, and (iii) relocation payments to employees of the Partnership for relocation resulting from the shared services integration and the relocation of the Partnership’s headquarters to Dallas, Texas. These retention payments are incremental to the affected employees’ base pay. For the three months ended March 31, 2026, severance charges and other employee costs included $0.6 million and $0.2 million related to retention and relocation payments, respectively. For the three months ended December 31, 2025, severance charges and other employee costs included $0.1 million and $(0.1) million related to retention and relocation payments, respectively. For the three months ended March 31, 2025, severance charges and other employee costs included $0.4 million and $0.1 million related to retention and relocation payments, respectively.

(4)

Represents incremental cash income tax expense accrued for the period presented as a result of the IRS examination of our tax returns for the federal tax years 2019 and 2020.

(5)

For the three months ended December 31, 2025, the loss on extinguishment of debt of $3.0 million is a result of the redemption of our senior notes due 2027.

(6)

Represents non-cash charges incurred to decrease the carrying value of long-lived assets with recorded values that are not expected to be recovered through future cash flows.

(7)

Reflects actual maintenance capital expenditures for the periods presented. Maintenance capital expenditures are capital expenditures made to maintain the operating capacity of the Partnership’s assets and extend their useful lives, replace partially or fully depreciated assets, or other capital expenditures that are incurred in maintaining the Partnership’s existing business and related cash flow.

(8)

Represents distributions to the holders of the Partnership’s common units as of the record date.

Key Takeaways USAC posted Q1 adjusted profit of 27 cents per unit as revenues climbed 35.1% year over year.USA Compression boosted revenue-generating capacity to 4.44M horsepower after the J-W Power deal.USAC reaffirmed 2026 EBITDA guidance of $770M-$800M and DCF outlook of $480M-$510M. USA Compression Partners (USAC - Free Report) reported first-quarter 2026 adjusted net profit of 27 cents per common unit, matching the Zacks Consensus Estimate. The metric improved from the year-ago quarter’s net profit of 18 cents per common unit, driven by a year-over-year increase in revenue-generating capacity and the contribution from the J-W Power acquisition.

The largest independent provider of natural gas compression services generated revenues of $331.3 million, improving 35.2% from the year-ago quarter’s level and beating the Zacks Consensus Estimate by 13.3%. This growth was aided by higher contract operations revenues and the inclusion of J-W Power’s results following the Jan. 12, 2026, acquisition.

Dallas, TX-based oil and gas equipment and services company’s adjusted EBITDA increased 26.1% to $188.6 million from $149.5 million in the prior-year quarter. Distributable cash flow rose to $130.8 million from $88.7 million in the year-ago period. The company reported net income of $38.3 million compared with $20.5 million in the year-ago quarter.

USAC reported net operating cash flow of $86.1 million in the first quarter, up from the prior-year quarter’s $54.7 million.

USAC’s Operational PerformanceThe company’s revenue-generating capacity increased year over year to 4.44 million horsepower from 3.56 million horsepower, primarily reflecting the J-W Power acquisition. Moreover, the figure exceeded our estimate of 3.58 million horsepower.

Adjusted gross operating margin of 64.4% marked a decrease from the year-ago period’s 66.7%. Further, the average monthly revenue per horsepower rose to $22.73 from $21.06 in the first quarter of 2025. However, the figure missed our estimate of $25.01 million average monthly revenue per horsepower.

USA Compression’s average quarterly horsepower utilization rate was 91.9%, down from the year-ago quarter’s 94.4%.

USAC’s DCF, Cost, Capex & Balance SheetUSA Compression’s distributable cash flow available to limited partners totaled $130.8 million, providing 1.72x distribution coverage, up from the year-ago level of 1.44x.

The company reported $239.9 million in costs and expenses, up from $175.8 million in the year-ago quarter. It spent $26.4 million on growth capex. Maintenance capex amounted to $9.2 million.

As of March 31, 2026, USA Compression had net long-term debt of $3 billion. The partnership had $497.8 million of remaining unused availability under its revolving credit facility.

USAC’s GuidanceUSA Compression reaffirmed its full-year 2026 outlook. This Zacks Rank #3 (Hold) company expects adjusted EBITDA to be between $770 million and $800 million. It also expects distributable cash flow to range from $480 million to $510 million, expansion capital expenditures to be between $230 million and $250 million, and maintenance capital expenditures to total in the band of $60 million to $70 million.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Important Earnings at a GlanceWhile we have discussed USAC’s first-quarter results in detail, let us take a look at three other key reports in this space.

Houston, TX-based oil and gas equipment and services provider, Halliburton Company (HAL - Free Report) , posted first-quarter 2026 adjusted net income per share of 55 cents, beating the Zacks Consensus Estimate of 49 cents. The outperformance primarily reflects successful cost reduction initiatives. However, the bottom line fell from the year-ago adjusted profit of 60 cents.

Halliburton reported first-quarter capital expenditure of $192 million. As of March 31, 2026, this oil and gas equipment and services company had approximately $2 billion in cash/cash equivalents and $7.1 billion in long-term debt, representing a debt-to-capitalization ratio of 39.6.

Houston, TX-based oil and gas storage and transportation company, Kinder Morgan Inc. (KMI - Free Report) , posted first-quarter 2026 adjusted earnings per share of 48 cents, which beat the Zacks Consensus Estimate of 38 cents. The bottom line increased year over year from 34 cents. The strong quarterly results can be primarily attributed to contributions from the Natural Gas Pipelines business segment.

As of March 31, 2026, KMI reported $72 million in cash and cash equivalents. At the quarter's end, its long-term debt amounted to $29.72 billion. KMI’s project backlog was reported at $10.1 billion by the end of the first quarter. The midstream energy major added that natural gas projects comprise approximately 92% of its project backlog, with nearly 60% dedicated to supporting local distribution companies and power generation.

Fort Worth, TX-based oil and gas exploration and production company, Range Resources Corporation (RRC - Free Report) , posted first-quarter 2026 adjusted earnings of $1.52 per share, which beat the Zacks Consensus Estimate of $1.33. The bottom line also improved from the prior-year level of 96 cents. Strong quarterly results can be attributed to higher gas-equivalent production and increased natural gas price realization.

Drilling and completion expenditure totaled $130 million. An additional $5 million was spent on acreage and $4 million on infrastructure and other investments. At the end of the first quarter, Range Resources reported a total debt of $819.3 million, net of deferred financing costs.

DALLAS--(BUSINESS WIRE)--USA Compression Partners, LP (NYSE: USAC) (“USA Compression”) today announced that its 2025 Schedule K-3 reflecting items of international tax relevance is available online. Unitholders requiring this information may access their Schedule K-3 at taxpackagesupport.com/usac. A limited number of unitholders (primarily foreign unitholders, unitholders computing a foreign tax credit on their tax return and certain corporate and/or partnership unitholders) may need the detail.

Sales of $593 million increased 22 percent and 19 percent on a reported and organic basis, respectively Operating income of $79 million and adjusted operating income of $82 million, up 80 percent and 64 percent, respectively Earnings per diluted share (EPS) of $0.75 and adjusted EPS of $0.77, up 85 percent and 65 percent, respectively Company raises annual sales and adjusted EPS Outlook PITTSBURGH, May 6, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) (the "Company") today reported results for its fiscal 2026 third quarter ended March 31, 2026. "Our third quarter results exceeded the high end of our sales and adjusted EPS Outlook, primarily due to the unprecedented rise in tungsten pricing and stronger volume," said Sanjay Chowbey, President and CEO.

Kennametal Inc. (KMT) Q3 2026 Earnings Call Transcript

KMT beats Q3 fiscal 2026 estimates as sales jump 22%, margins expand and Earthworks, Energy and Aerospace demand stay strong.

Investors interested in Manufacturing - Tools & Related Products stocks are likely familiar with Kennametal (KMT) and Sandvik AB (SDVKY). But which of these two stocks is more attractive to value investors?

PITTSBURGH, May 18, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the KeyBanc Capital Markets 2026 Industrials & Basic Materials Conference in Boston. Details of the conference are as follows: When:   Wednesday, May 27, 2026   Attendees: Sanjay Chowbey, President and Chief Executive Officer Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About Kennametal With over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions.